6th IAS Conference On HIV Pathogenesis, Treatment and Prevention

ART and Clinical Outcomes TUPDB01

Type:
Oral Poster Discussion Back
Venue: SR 3
Time: 13:00 - 14:00, 19.07.2011
Code: TUPDB01
Chair: Antonella d'Arminio Monforte, Italy



Presentations in this session:

13:00
TUPDB0101
Abstract
HIV treatment guidelines and value of CD4 count at ART initiation: data analysis of a cohort of HIV patients enrolled in Italy when their CD4 count was >500 cells/mm3
Presented by Sergio Lo Caputo, Italy
S. Lo Caputo1, A. Cozzi-Lepri2, A. Antinori3, M. Galli4, P.L. Viale5, A. Lazzarin6, G. Carosi7, L. Sighinolfi8, M. Montroni9, A. d'Arminio Monforte10
1S.M. Annunziata Hospital, Infectious Disease Clinic, florence, Italy, 2University College London, london, United Kingdom, 3INMI Lazzaro Spallanzani, Roma, Italy, 4Dipartimento Scienze Cliniche- Università di Milano Ospedale Luigi Sacco, Milano, Italy, 5Clinica Malattia Infettive Ospedale Sant'Orsola Università degli Studi Bologna, Bologna, Italy, 6Clinica Malattie Infettive Osp. San Raffaele, milano, Italy, 7Istituto Malattie Infettive Università di Brescia, Brescia, Italy, 8U.O. Malattie Infettive Azienda Ospedaliera Universitaria Arcispedale S. Anna, Ferrara, Italy, 9Clinica Malattie Infettive Università degli Studi Ancona, Ancona, Italy, 10Clinica Malattie Infettive - Ospedale San Paolo, Milano, Italy

13:05
TUPDB0102
Abstract
Powerpoint
Monitoring and outcomes of ART: mathematical model based on IeDEA Southern Africa
Presented by Janne Estill, Switzerland
J. Estill1, T. Hallett2, D. Garone3, L. Johnson4, R. Wood5, M. Egger1, O. Keiser1
1University of Bern, Institute of Social and Preventive Medicine, Bern, Switzerland, 2Imperial College London, Department of Infectious Disease Epidemiology, London, United Kingdom, 3Khayelitsha ART Programme, Cape Town, South Africa, 4University of Cape Town, Centre for Infectious Disease Epidemiology & Research, Cape Town, South Africa, 5University of Cape Town, Desmond Tutu HIV Centre, Cape Town, South Africa

13:10
TUPDB0103
Abstract
Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1 infected naive patients with high CD4 counts
Presented by Silvia Nozza, Italy
S. Nozza1, F. Canducci2, L. Galli1, A. Cozzi-Lepri3, M.R. Capobianchi4, E. Ceresola2, A. Antinori4, S. Di Giambenedetto5, A. d'Arminio Monforte3, A. Castagna1,3, ICONA Foundation
1San Raffaele Scientific Institute, Infectious Diseases, Milano, Italy, 2San Raffaele Scientific Institute, Milano, Italy, 3ICONA Foundation, Milan, Italy, 4IRCCS Spallanzani, Rome, Italy, 5Catholic University, Rome, Italy

13:15
TUPDB0104
Abstract
Powerpoint
Trend over calendar time in virological failure in HIV-infected patients treated for at least six months with combined antiretroviral therapy in France (FHDH ANRS CO04)
Presented by Dominique Costagliola, France
C. Delaugerre1, J. Ghosn2, J.-M. Lacombe3, G. Pialoux4, L. Cuzin5, O. Launay6, A. Menard7, P. de Truchis8, D. Costagliola9, FHDH ANRS CO04
1Hopital Saint Louis, Paris, France, 2Hopital Kremlin Bicetre, Infectious Diseases-Internal Medecine, Kremlin Bicetre, France, 3U943 INSERM, Paris, France, 4Hopital Tenon, Infectious Diseases, Paris, France, 5CHU Toulouse, Infectious Diseases, Toulouse, France, 6Hopital Cochin, CIC BT505, Paris, France, 7Hopital Sainte Marguerite, Marseille, France, 8Hopital Raymond Poincaré, Infectious Diseases, Garches, France, 9U943 INSERM, Université Pierre et Marie Curie, Paris, France

13:20
TUPDB0105
Abstract
Powerpoint
Are patients on HAART in Uganda experiencing less treatment failure than earlier anticipated? A case study of Mbarara RCE HAART clinic
Presented by Francis Kiweewa, Uganda
F. Kiweewa1, A. Lugemwa2, H. Namata3, N. Musinguzi2, W. Muyindiike2, A.F. Nakirijja1, C. Kityo1, P. Mugyenyi1
1Joint Clinical Research Center, Research and Development, Kampala, Uganda, 2Mbarara Rgional Center of Excellence-JCRC, Clinical, Mbarara, Uganda, 3Joint Clinical Research Centre, Biostatistics, Kampala, Uganda

13:25
TUPDB0106
Abstract
Powerpoint
Reaching 500 CD4 cells/µl is associated with higher survival after 9 months on ART in Sub-Saharan African patients
Presented by David Maman, France
D. Maman1,2, M. Pujades-Rodriguez1, S. Nicholas1, M. McGuire3, R. Ecochard2, J.-F. Etard1
1Epicentre, Clinical Research Department, Paris, France, 2Hospices Civils de Lyon, Department of Biostatistics, Lyon, France, 3Epicentre, Clinical research department, Paris, France

13:30
Moderated discussion





Powerpoints presentations
Monitoring and outcomes of ART: mathematical model based on IeDEA Southern Africa - Janne Estill


Trend over calendar time in virological failure in HIV-infected patients treated for at least six months with combined antiretroviral therapy in France (FHDH ANRS CO04) - Dominique Costagliola

Are patients on HAART in Uganda experiencing less treatment failure than earlier anticipated? A case study of Mbarara RCE HAART clinic - Francis Kiweewa

Reaching 500 CD4 cells/µl is associated with higher survival after 9 months on ART in Sub-Saharan African patients - David Maman



   

    The organizers reserve the right to amend the programme.


Contact Us | Site map © 2011 International AIDS Society